ibrance palbociclib 75 mg capsule blister pack
pfizer australia pty ltd - palbociclib, quantity: 75 mg - capsule, hard - excipient ingredients: silicon dioxide; iron oxide yellow; iron oxide red; titanium dioxide; magnesium stearate; sodium starch glycollate type a; gelatin; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.
ibrance palbociclib 125 mg capsule blister pack
pfizer australia pty ltd - palbociclib, quantity: 125 mg - capsule, hard - excipient ingredients: gelatin; sodium starch glycollate type a; iron oxide yellow; silicon dioxide; magnesium stearate; titanium dioxide; iron oxide red; lactose monohydrate; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; simethicone; ethanol; shellac; sulfuric acid - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.
vizimpro
pfizer europe ma eeig - dacomitinib monohydrate - carcinoma, non-small-cell lung - antineoplastic agents - vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (nsclc) with epidermal growth factor receptor (egfr) activating mutations.
ibrance palbociclib 125 mg tablet blister pack
pfizer australia pty ltd - palbociclib, quantity: 125 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide red; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.
ibrance palbociclib 100 mg tablet blister pack
pfizer australia pty ltd - palbociclib, quantity: 100 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.
ibrance palbociclib 75 mg tablet blister pack
pfizer australia pty ltd - palbociclib, quantity: 75 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; silicon dioxide; crospovidone; magnesium stearate; succinic acid; titanium dioxide; hypromellose; triacetin; iron oxide red; indigo carmine aluminium lake - ibrance is indicated for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy.
regen-d 150 recombinant human epidermal growth factor gel
recombinant human epidermal growth factor
regen-d 60 recombinant human epidermal growth factor gel
recombinant human epidermal growth factor 60ug
maxim orderly solution
project clean inc - octyl decyl dimethyl ammonium chloride; dioctyl dimethyl ammonium chloride; didecyl dimethyl ammonium chloride; benzalkonium chloride - solution - 1.627%; 0.814%; 0.814%; 2.17% - octyl decyl dimethyl ammonium chloride 1.627%; dioctyl dimethyl ammonium chloride 0.814%; didecyl dimethyl ammonium chloride 0.814%; benzalkonium chloride 2.17% - disinfectants (for agents used on object)
promax orderly solution
project clean inc - octyl decyl dimethyl ammonium chloride; dioctyl dimethyl ammonium chloride; didecyl dimethyl ammonium chloride; benzalkonium chloride - solution - 1.627%; 0.814%; 0.814%; 2.17% - octyl decyl dimethyl ammonium chloride 1.627%; dioctyl dimethyl ammonium chloride 0.814%; didecyl dimethyl ammonium chloride 0.814%; benzalkonium chloride 2.17% - disinfectants (for agents used on object)